Market open
Niagen Bioscience/$NAGE
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Niagen Bioscience
Niagen Bioscience Inc is the leader in NAD+ (nicotinamide adenine dinucleotide) science and healthy-aging research. It is dedicated to advancing healthspan through precision science and innovative NAD+-boosting solutions. It is is clinically proven to increase NAD+ levels efficiently and effectively, and is the key ingredient powering our suite of Niagen brands.
Ticker
$NAGE
Sector
Trading on
Industry
Life Sciences Tools & Services
Headquarters
Employees
104
Website
NAGE Metrics
BasicAdvanced
$517M
60.27
$0.11
2.21
-
Price and volume
Market cap
$517M
Beta
2.21
52-week high
$9.18
52-week low
$2.31
Average daily volume
1.3M
Financial strength
Current ratio
3.572
Quick ratio
2.963
Long term debt to equity
3.595
Total debt to equity
5.751
Management effectiveness
Return on assets (TTM)
7.84%
Return on equity (TTM)
22.94%
Valuation
Price to earnings (TTM)
60.273
Price to revenue (TTM)
5.054
Price to book
11.15
Price to tangible book (TTM)
11.23
Price to free cash flow (TTM)
42.14
Growth
Revenue change (TTM)
19.18%
Earnings per share change (TTM)
-257.14%
3-year revenue growth (CAGR)
13.87%
3-year earnings per share growth (CAGR)
-35.17%
What the Analysts think about NAGE
Analyst Ratings
Analyst ratings (Buy, Hold, Sell) for Niagen Bioscience stock.
NAGE Financial Performance
Income Statement
Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%
NAGE Earnings Performance
Earnings per share (EPS)
Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
NAGE News
AllArticlesVideos
Niagen Bioscience Secures U.S. Patent for the Composition of Matter for Nicotinamide Riboside (NR) Salt Forms
Business Wire·2 weeks ago
ChromaDex Evolves Into Niagen Bioscience, Marking a New Era of Uncovering the Potential of NAD+ With Precision Science
Business Wire·2 weeks ago
ChromaDex Corp. Announces Name Change to Niagen Bioscience, Inc. and New Ticker Symbol "NAGE" Effective March 19, 2025
Business Wire·3 weeks ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
FAQs
What’s the current market cap for Niagen Bioscience stock?
Niagen Bioscience (NAGE) has a market cap of $517M as of April 04, 2025.
What is the P/E ratio for Niagen Bioscience stock?
The price to earnings (P/E) ratio for Niagen Bioscience (NAGE) stock is 60.27 as of April 04, 2025.
Does Niagen Bioscience stock pay dividends?
No, Niagen Bioscience (NAGE) stock does not pay dividends to its shareholders as of April 04, 2025.
When is the next Niagen Bioscience dividend payment date?
Niagen Bioscience (NAGE) stock does not pay dividends to its shareholders.
What is the beta indicator for Niagen Bioscience?
Niagen Bioscience (NAGE) has a beta rating of 2.21. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.